Agenus to Present at the 2016 JMP Securities Life Sciences Conference
June 15 2016 - 8:50AM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company
developing antibodies including checkpoint inhibitors and other
checkpoint modulators, and cancer vaccines, today announced that
Robert B. Stein, M.D., Ph.D., President, Research &
Development, will present at the 2016 JMP Securities Life Sciences
Conference on Wednesday, June 22nd at 3:30 p.m. ET. The conference
will take place at the St. Regis New York in New York City.
Webcast Information
The live and archived webcast of the presentation will be
accessible from the Company’s website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before the event to ensure
a timely connection. The archived replay will be available on the
Agenus website for one month following the conference.
About Agenus
Agenus is an immuno-oncology company focused on the discovery
and development of revolutionary new treatments that engage the
body’s immune system to benefit patients suffering from cancer. By
combining multiple powerful platforms, Agenus has established a
highly integrated approach for the discovery, development and
manufacture of monoclonal antibodies that modulate targets of
interest. In addition, the Company’s cancer vaccine program
includes three proprietary platforms focused on individualized and
off-the-shelf vaccines uniquely designed for each patient. Agenus’
broad portfolio of novel checkpoint and other immuno-modulatory
monoclonal antibodies, vaccines and adjuvants, work in combination
to provide the opportunity to create best-in-class therapeutic
regimens. The Company has formed collaborations with Merck and
Incyte to discover and develop multiple checkpoint antibodies. For
more information, please visit www.agenusbio.com; information that
may be important to investors will be routinely posted on our
website.
Forward-Looking Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company’s
upcoming presentation. These forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or annual report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160615005372/en/
Agenus Inc.Michelle Linn,
781-674-4541michelle.linn@agenusbio.comorMedia:BMC
CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024